メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
感染症学講座
富山大学
医学系
概要
フィンガープリント
ネットワーク
プロファイル
(5)
プロジェクト
(9)
研究成果
(258)
データセット
(11)
フィンガープリント
感染症学講座が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Japan
100%
Methicillin-resistant Staphylococcus Aureus
68%
COVID-19
62%
Linezolid
57%
Streptococcus Pneumoniae
48%
Lung
47%
Murine Model
41%
Pneumonia
40%
Pulmonary Cryptococcosis
39%
Pseudomonas Aeruginosa (P. aeruginosa)
38%
Nagasaki
37%
Community-acquired Pneumonia
30%
In Vivo Efficacy
29%
Respiratory Infection
28%
Clinical Characteristics
27%
Vancomycin
27%
Cryptococcus Neoformans
25%
Clinical Efficacy
25%
Quantitative PCR
25%
S. Pneumoniae
25%
Thrombocytopenia
24%
Daptomycin
24%
Haemophilus Influenzae
24%
Mouse Model
23%
Clarithromycin
22%
Bacterial Pneumonia
22%
Amphotericin B
21%
Azithromycin
21%
Bacteremia
21%
Pulmonary Infection
21%
Antibiotics
20%
Pharmacokinetics
20%
Hematogenous
19%
Fluconazole
19%
Candida Glabrata
19%
Mucin 5AC (MUC5AC)
19%
Neoformans
19%
Levofloxacin
18%
Chest CT
18%
Older Men
18%
Acute Respiratory Tract Infection
18%
Candidemia
18%
Influenza Pneumonia
17%
Combination Therapy
17%
Minimum Inhibitory Concentration
17%
Influenza Virus
17%
Micafungin
17%
University Hospital
16%
Staphylococcus Aureus Bacteremia
16%
Rifampicin
16%
Fever
16%
Viral Load
16%
Therapeutic Drug Monitoring
16%
Mycobacterium Tuberculosis (M. tb)
16%
Airway Epithelial Cells
15%
Hospitalized Patients
15%
Fluoroquinolones
14%
Itraconazole
14%
Aspergillus Fumigatus
14%
Bronchoalveolar Lavage Fluid
14%
Piperacillin
14%
Biapenem
14%
Infectious Diseases
13%
Patients with COVID-19
13%
Ampicillin Resistance
13%
Adult Patients
13%
Immunocompromised Patients
13%
Cystic Fibrosis
13%
Sputum
13%
Chemotherapy
13%
Clinical Features
12%
β-lactamase
12%
Invasive Pulmonary Aspergillosis
12%
Viable Bacteria
12%
Carbapenems
12%
Neutralizing Antibodies
12%
Meropenem
12%
Cryptococcosis
12%
Rapid Detection
12%
Virulence
12%
Staphylococcus Aureus
12%
High Dose
12%
Macrolides
12%
Underlying Disease
12%
Sivelestat
11%
Healthcare-associated Pneumonia
11%
Ventilator-associated Pneumonia
11%
Garenoxacin
11%
Calcineurin
11%
Population Pharmacokinetics
11%
Adult Case
11%
Neutrophils
11%
Bacterial Infection
11%
Clinical Specimens
11%
Severe Pneumonia
11%
Fusobacterium nucleatum (F. nucleatum)
11%
Cryptococcus
11%
Candida
11%
Resistant Strains
11%
Survival Rate
11%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
75%
Methicillin-Resistant Staphylococcus Aureus
62%
Linezolid
57%
Pharmacokinetics
41%
Respiratory Tract Infection
37%
SARS Coronavirus
36%
Pseudomonas aeruginosa
35%
Methicillin Resistant Staphylococcus Aureus Infection
32%
Community Acquired Pneumonia
26%
Disease
25%
Thrombocytopenia
24%
Daptomycin
23%
Antiinfective Agent
23%
Amphotericin B
23%
Vancomycin
23%
Quinolone Derivative
19%
Bacterial Pneumonia
19%
Mouse Model
18%
Clarithromycin
18%
Levofloxacin
18%
Lung Infection
17%
Combination Therapy
17%
Bloodstream Infection
17%
Streptococcus
15%
Mucin 5AC
15%
Macrolide
15%
Antibiotics
15%
Haemophilus influenzae
15%
Therapeutic Drug Monitoring
15%
Coronavirinae
15%
Invasive Aspergillosis
14%
Lung Aspergillosis
14%
Azithromycin
13%
Micafungin
13%
Pharmacodynamics
13%
Cohort Study
13%
Antifungal Agent
13%
Aspergillus
13%
Legionella pneumophila
13%
Infectious Agent
13%
Itraconazole
13%
Penicillinase
12%
Aspergillus fumigatus
12%
Health Care Associated Pneumonia
12%
Biapenem
12%
Meropenem
12%
Staphylococcus Aureus
12%
Sivelestat
11%
Legionella
11%
Clinical Feature
11%
Adverse Event
11%
Mycosis
11%
Lung Abscess
11%
Pulmonary Cryptococcosis
10%
Candida
10%
Pazufloxacin
10%
Sitafloxacin
10%
Piperacillin
10%
Hemodialysis
10%
Streptococcus Pneumonia
10%
Mortality Rate
10%
Cytokine
10%
Lipopolysaccharide
9%
Neutralizing Antibody
9%
Clinical Trial
9%
Inflammation
9%
Fluconazole
9%
Interleukin 6
9%
Carbapenem
9%
Disease Severity
9%
Erythromycin
9%
Piperacillin Plus Tazobactam
9%
Rifampicin
9%
Sultamicillin
9%
Fusobacterium nucleatum
8%
Clinical Study
8%
Sepsis
8%
Teicoplanin
8%
Gatifloxacin
8%
Randomized Controlled Trial
8%
Ampicillin
8%
Minimum Inhibitory Concentration
8%
Agar
8%
Respiratory Failure
8%
Garenoxacin
7%
Ciprofloxacin
7%
Coagulase
7%
Mycobacterium Avium Complex
7%
Ventilator Associated Pneumonia
7%
Coccidioidomycosis
7%
Interferon Type I
7%
Prevotella intermedia
7%
Flucytosine
7%
Lung Disease
7%
Legionnaire Disease
7%
Survival Rate
7%
Favipiravir
6%
Panton-Valentine Leukocidin
6%
Fatality
6%
Creatinine
6%
Medicine and Dentistry
Infection
53%
COVID-19
38%
Pneumococcus
22%
Pathogen
22%
Respiratory Tract Infection
22%
Lung
21%
Severe Acute Respiratory Syndrome Coronavirus 2
19%
Community-Acquired Pneumonia
18%
Bloodstream Infection
18%
Sputum
18%
Antiinfective Agent
17%
Computer Assisted Tomography
17%
Chemotherapy
15%
Disease
15%
Pseudomonas aeruginosa
13%
Antibiotics
13%
Amphotericin B
12%
Bacterial Pneumonia
12%
Methicillin Resistant Staphylococcus Aureus
12%
Pulmonary Cryptococcosis
11%
Invasive Aspergillosis
11%
Respiratory Failure
10%
Lung Abscess
9%
Micafungin
9%
Coughing
9%
Silo-Filler's Disease
9%
Streptococcus Pneumonia
9%
Penicillinase
9%
Clinical Trial
9%
Pneumococcal Infection
9%
Blood Culture
9%
Cystic Fibrosis
8%
Reverse Transcription Polymerase Chain Reaction
8%
Chest Radiograph
8%
Health Care Associated Pneumonia
8%
Cohort Study
8%
Clinical Feature
8%
Serotype
8%
Haemophilus influenzae
8%
Legionella pneumophila
8%
Meropenem
8%
Pneumococcal Pneumonia
8%
Influenza Virus
7%
Piperacillin/Tazobactam
7%
Lung Aspergillosis
7%
Endocarditis
7%
Erysipelothrix rhusiopathiae
7%
Itraconazole
7%
Empyema
7%
Lung Transplantation
7%
Human Immunodeficiency Virus
7%
Abscess
7%
Ground Glass Opacity
7%
Fulminant
7%
Aspergillus
7%
Vancomycin
7%
Differential Diagnosis
7%
Interleukin 6
7%
Mixed Infection
6%
Pathogenicity
6%
Gram Staining
6%
Klebsiella pneumoniae
6%
Fusobacterium nucleatum
6%
Methicillin Resistant Staphylococcus Aureus Infection
6%
Tuberculosis
5%
High Fever
5%
Ampicillin
5%
Piperacillin
5%
Cryptococcosis
5%
Nocardiosis
5%
Thrombocyte Activating Factor Receptor
5%
Prevotella intermedia
5%
Decision Making
5%
Clinical Study
5%
Biapenem
5%
Bronchoalveolar Lavage Fluid
5%
Drug Megadose
5%
Magnetic Resonance Imaging
5%
Antibiogram
5%
Antifungal Agent
5%
Ampicillin/Sulbactam
5%
Cohort Effect
5%